Receptor for Advanced Glycation End Products Is Involved in Impaired Angiogenic Response in Diabetes
- Takuhito Shoji1,
- Hidenori Koyama1,
- Tomoaki Morioka1,
- Shinji Tanaka1,
- Akane Kizu1,
- Kohka Motoyama1,
- Katsuhito Mori1,
- Shinya Fukumoto1,
- Atsushi Shioi2,
- Noriko Shimogaito3,
- Masayoshi Takeuchi3,
- Yasuhiko Yamamoto4,
- Hideto Yonekura4,
- Hiroshi Yamamoto4 and
- Yoshiki Nishizawa1
- 1Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan
- 2Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan
- 3Department of Pathophysiological Science, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan
- 4Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
- Address correspondence and reprint requests to Hidenori Koyama, MD, PhD, Department of Metabolism, Endocrinology and Molecular Medicine, (Second Department of Internal Medicine), Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. E-mail: hidekoyama{at}med.osaka-cu.ac.jp
Abstract
Angiogenic response is impaired in diabetes. Here, we examined the involvement of receptor for advanced glycation end products (RAGE) in diabetes-related impairment of angiogenesis in vivo. Angiogenesis was determined in reconstituted basement membrane protein (matrigel) plugs containing vascular endothelial growth factor (VEGF) implanted into nondiabetic or insulin-deficient diabetic wild-type or RAGE−/− mice. The total, endothelial, and smooth muscle (or pericytes) cells in the matrigel were significantly decreased in diabetes, with the regulation dependent on RAGE. In the matrigel, proangiogenic VEGF expression was decreased, while antiangiogenic thrombospondin-1 was upregulated in diabetic mice, regardless of the presence of RAGE. In wild-type mice, proliferating cell nuclear antigen (PCNA)-positive cells in the matrigel were significantly less in diabetic than in nondiabetic mice, while the numbers of transferase-mediated dUTP nick-end labeling (TUNEL)-positive cells were significantly higher. This alteration in PCNA- and TUNEL-positive cells in diabetes was not observed in RAGE−/− mice. Similarly, the percentage of nuclear factor κB–activated cells is enhanced in diabetes, with the regulation dependent on the presence of RAGE. Importantly, adenovirus-mediated overexpression of endogenous secretory RAGE, a decoy receptor for RAGE, restores diabetes-associated impairment of angiogenic response in vivo. Thus, RAGE appears to be involved in impairment of angiogenesis in diabetes, and blockade of RAGE might be a potential therapeutic target.
- αSM actin, α smooth muscle actin
- Ad-esRAGE, pAdHM15-esRAGE
- AGE, advanced glycation end product
- CML, N-carboxymethyllysine
- esRAGE, endogenous secretory RAGE
- MMP, matrix metalloproteinase
- NF-κB, nuclear factor-κB
- PCNA, proliferating cell nuclear antigen
- RAGE, receptor for AGE
- STZ, streptozotocin
- TSP, thrombospondin
- TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling
- VEGF, vascular endothelial growth factor
Footnotes
-
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Accepted May 17, 2006.
- Received October 23, 2005.
- DIABETES











